Paliperidone palmitate for use in a method of treating psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar disorder, the method comprising administering paliperidone palmitate to a patient in need thereof who has been administered a first dose of a first paliperidone palmitate extended-release injectable suspension having a six month dosing interval ("PP6M") (first suspension), comprising: administering in a deltoid muscle of the patient a re-initiation loading dose of a second paliperidone palmitate extended-release injectable suspension having a one month dosing interval ("PP1M") (second suspension) at a time that is more than six months and three weeks after administration of said first dose of the first suspension but less than eight months after administration of said first dose of the first suspension; and administering in the deltoid or gluteal muscle of the patient a maintenance dose of the first suspension at a time that is one month (± 7 days) after administering the re-initiation loading dose of the second suspension, wherein there are no intervening doses of paliperidone palmitate between the first dose and the re-initiation loading dose, wherein the PP6M (first suspension) comprises about 312 mg/mL of paliperidone palmitate; wherein the PP1M (second suspension) comprises about 156 mg/mL of paliperidone palmitate; wherein the paliperidone palmitate extended-release injectable suspensions are aqueous compositions further comprising a suspending agent, a buffer, and optionally one or more of a preservative and an isotonizing agent, and wherein either (i) the first dose of the first suspension comprises about 1092 mg of paliperidone palmitate; the re-initiation loading dose of the second suspension comprises about 156 mg of paliperidone palmitate; and the maintenance dose of the first suspension comprises about 1092 mg of paliperidone palmitate, or (ii) the first dose of the first suspension comprises about 1560 mg of paliperidone palmitate; the re-initiation loading dose of the second suspension comprises about 234 mg of paliperidone palmitate; and the maintenance dose of the first suspension comprises about 1560 mg of paliperidone palmitate. administering in a deltoid muscle of the patient a re-initiation loading dose of a second paliperidone palmitate extended-release injectable suspension having a one month dosing interval ("PP1M") (second suspension) at a time that is more than six months and three weeks after administration of said first dose of the first suspension but less than eight months after administration of said first dose of the first suspension; and administering in the deltoid or gluteal muscle of the patient a maintenance dose of the first suspension at a time that is one month (± 7 days) after administering the re-initiation loading dose of the second suspension, wherein there are no intervening doses of paliperidone palmitate between the first dose and the re-initiation loading dose, wherein the PP6M (first suspension) comprises about 312 mg/mL of paliperidone palmitate; wherein the PP1M (second suspension) comprises about 156 mg/mL of paliperidone palmitate; wherein the paliperidone palmitate extended-release injectable suspensions are aqueous compositions further comprising a suspending agent, a buffer, and optionally one or more of a preservative and an isotonizing agent, and wherein either (i) the first dose of the first suspension comprises about 1092 mg of paliperidone palmitate; the re-initiation loading dose of the second suspension comprises about 156 mg of paliperidone palmitate; and the maintenance dose of the first suspension comprises about 1092 mg of paliperidone palmitate, or (ii) the first dose of the first suspension comprises about 1560 mg of paliperidone palmitate; the re-initiation loading dose of the second suspension comprises about 234 mg of paliperidone palmitate; and the maintenance dose of the first suspension comprises about 1560 mg of paliperidone palmitate. (i) the first dose of the first suspension comprises about 1092 mg of paliperidone palmitate; the re-initiation loading dose of the second suspension comprises about 156 mg of paliperidone palmitate; and the maintenance dose of the first suspension comprises about 1092 mg of paliperidone palmitate, or (ii) the first dose of the first suspension comprises about 1560 mg of paliperidone palmitate; the re-initiation loading dose of the second suspension comprises about 234 mg of paliperidone palmitate; and the maintenance dose of the first suspension comprises about 1560 mg of paliperidone palmitate.